Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching-Reference-Cited by-同舟云学术

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching

Published:2018-08-27 Issue:10 Volume:7 Page:4893-4902
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Onozawa Mizuki¹^ORCID,Akaza Hideyuki²,Hinotsu Shiro³,Oya Mototsugu⁴,Ogawa Osamu⁵,Kitamura Tadaichi⁶,Suzuki Kazuhiro⁷,Naito Seiji⁸,Namiki Mikio⁹,Nishimura Kazuo¹⁰,Hirao Yoshihiko¹¹,Tsukamoto Taiji¹²

Affiliation:

1. Department of Urology; School of Medicine; International University of Health and Welfare; Chiba Japan

2. Research Center for Advanced Science and Technology; University of Tokyo; Tokyo Japan

3. Department of Biostatistics and Clinical Epidemiology; Sapporo Medical University; Sapporo Japan

4. Department of Urology; School of Medicine; Keio University; Tokyo Japan

5. Department of Urology; Kyoto University Graduate School of Medicine; Kyoto Japan

6. Department of Urology; Shinsui Clinic; Tokyo Japan

7. Department of Urology; Gunma University Graduate School of Medicine; Gunma Japan

8. Department of Urology; Harasanshin Hospital; Fukuoka Japan

9. Department of Urology; Hasegawa Hospital; Toyama Japan

10. Department of Urology; Osaka International Cancer Institute; Osaka Japan

11. Department of Urology; Osaka Gyoumeikan Hospital; Osaka Japan

12. Department of Urology; Sapporo Medical University; Sapporo Japan

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.1735/fullpdf

Reference28 articles.

1. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer;Cooperberg;Cancer,2010

2. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan;Onozawa;Jpn J Clin Oncol,2014

3. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer;Cooperberg;BJU Int,2016

4. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival;Labrie;J Steroid Biochem,1985

5. Current status of endocrine therapy for prostate cancer in Japan-analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP;Hinotsu;Jpn J Clin Oncol,2007

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer;Global Health & Medicine;2024-06-30

2. Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer;Scientific Reports;2024-01-06

3. Unraveling the Peculiar Features of Mitochondrial Metabolism and Dynamics in Prostate Cancer;Cancers;2023-02-13

4. Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study;International Journal of Clinical Oncology;2022-08-10

5. Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study;BJUI Compass;2021-08-20